Dorfman Lev, El-Chammas Khalil, Graham Kahleb, Sahay Rashmi, Hardy Jennifer, Kaul Ajay, Santucci Neha
Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach-Tikva, Israel.
J Pediatr Gastroenterol Nutr. 2025 Aug;81(2):234-245. doi: 10.1002/jpn3.70109. Epub 2025 Jun 11.
Percutaneous electrical nerve field stimulation (PENFS) is an FDA-approved nonpharmacological modality for treating disorders of gut-brain interaction (DGBI) in pediatric patients. PENFS presumably functions through stimulation of cranial nerves. There is limited data on patients that require more than a 4-week cycle of treatment with PENFS. We examined the effect of repeated rounds of PENFS on recurrent symptoms and predictors for multiple treatments.
We evaluated charts of patients who underwent PENFS placement for DGBI. Data included demographics, medical history, and validated questionnaire responses. Changes over time after each round of placement were assessed. Baseline measures were compared between patients with single versus two rounds.
A total of 22 patients (median age 17.5 years, 18 (82%) females) with repeated PENFS met the inclusion criteria. A propensity-matched control group (n = 22) showed no significant differences in demographics or diagnoses. Patients requiring repeated PENFS placements had higher PCS-C scores (median 24.5 (IQR 18-28) vs. 16.5 (IQR 9.5-22.5); p = 0.0135), and higher PHQ-9 scores (median 10 (IQR 8-14) vs. 7 (IQR 7.5-9.5); p = 0.0272). The second round of PENFS placements significantly reduced API, PCS-C, FDI, PHQ-9, and CSI scores (p < 0.05). No statistically significant differences between scores after the first and second rounds were noted.
Repeating PENFS treatments are becoming common in clinical practice. Our study shows that repeat rounds are as effective as the initial ones, with pain catastrophizing and depression predicting worse outcomes and the need for repeat and/or longer round of treatment.
经皮电神经场刺激(PENFS)是一种经美国食品药品监督管理局(FDA)批准的用于治疗儿科患者肠脑互动障碍(DGBI)的非药物治疗方法。PENFS可能通过刺激颅神经发挥作用。关于需要超过4周PENFS治疗周期的患者的数据有限。我们研究了重复多轮PENFS对复发症状的影响以及多次治疗的预测因素。
我们评估了因DGBI接受PENFS植入的患者病历。数据包括人口统计学信息、病史和经过验证的问卷回复。评估每轮植入后随时间的变化。比较单次植入与两次植入患者的基线测量值。
共有22例接受重复PENFS治疗的患者(中位年龄17.5岁,18例(82%)为女性)符合纳入标准。倾向评分匹配的对照组(n = 22)在人口统计学或诊断方面无显著差异。需要重复PENFS植入的患者PCS-C评分更高(中位数24.5(四分位间距18 - 28)对16.5(四分位间距9.5 - 22.5);p = 0.0135),PHQ-9评分也更高(中位数10(四分位间距8 - 14)对7(四分位间距7.5 - 9.5);p = 0.0272)。第二轮PENFS植入显著降低了API、PCS-C、FDI、PHQ-9和CSI评分(p < 0.05)。第一轮和第二轮评分之间未发现统计学显著差异。
在临床实践中,重复PENFS治疗变得越来越普遍。我们的研究表明,重复治疗轮次与初始轮次一样有效,疼痛灾难化和抑郁预示着更差的结果以及需要重复和/或更长疗程的治疗。